Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Thursday announced the availability of its US Food and Drug Administration (FDA) approved Cinacalcet Tablets in the United States.
Dr. Reddy's Cinacalcet Tablets are a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets. The Sensipar brand and generic market had US sales of approximately USD312m MAT for the 12 months ending in July 2020, according to IQVIA Health.
Cinacalcet Tablets are available in 30 mg, 60 mg and 90 mg tablets in a bottle count size of 30.
Cinacalcet is a medication used to treat secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism.
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)